TCG Crossover GP I Reports 0% Stake in Taysha Gene Therapies
Ticker: TSHA · Form: SC 13G/A · Filed: Feb 9, 2024 · CIK: 1806310
Complexity: simple
Sentiment: bearish
Topics: institutional-ownership, divestment, biotech, 13G/A
TL;DR
**TCG Crossover GP I has exited its reportable stake in Taysha Gene Therapies.**
AI Summary
TCG Crossover GP I, LLC, a Delaware-based entity, has filed an amended SC 13G/A for Taysha Gene Therapies, Inc. (NASDAQ: TSHA) as of December 31, 2023. This filing indicates that TCG Crossover GP I, LLC, along with its group member TCG Crossover Fund I, L.P. and CHEN YU, beneficially owns 0 shares with sole voting power in Taysha Gene Therapies. This matters to investors because it shows a significant institutional investor no longer holds a reportable beneficial ownership stake, which could signal a change in their investment strategy or outlook on Taysha Gene Therapies.
Why It Matters
This filing reveals a major institutional investor, TCG Crossover GP I, LLC, no longer holds a significant beneficial ownership in Taysha Gene Therapies, which could impact investor sentiment and stock valuation.
Risk Assessment
Risk Level: medium — The complete divestment of a reportable stake by an institutional investor can sometimes signal a lack of confidence, potentially increasing perceived risk for current and prospective shareholders.
Analyst Insight
A smart investor would investigate the reasons behind TCG Crossover GP I, LLC's complete divestment of its reportable stake in Taysha Gene Therapies and assess if there are any underlying negative developments before making investment decisions.
Key Numbers
- 0 — Shares with Sole Voting Power (TCG Crossover GP I, LLC's beneficial ownership in Taysha Gene Therapies as of December 31, 2023)
- 877619106 — CUSIP Number (Identifies Taysha Gene Therapies' Common Stock)
- December 31, 2023 — Date of Event (The date requiring this Schedule 13G/A filing)
Key Players & Entities
- TCG Crossover GP I, LLC (company) — the reporting person, a Delaware-based entity
- Taysha Gene Therapies, Inc. (company) — the subject company, a biological products firm
- TCG Crossover Fund I, L.P. (company) — a group member with TCG Crossover GP I, LLC
- CHEN YU (person) — a group member with TCG Crossover GP I, LLC
- 0 (dollar_amount) — number of shares with sole voting power beneficially owned by TCG Crossover GP I, LLC
Forward-Looking Statements
- Taysha Gene Therapies' stock price may experience short-term volatility due to the perceived lack of institutional confidence. (Taysha Gene Therapies, Inc.) — medium confidence, target: Q2 2024
- Other institutional investors might re-evaluate their positions in Taysha Gene Therapies following this divestment. (Institutional Investors) — low confidence, target: Q3 2024
FAQ
Who is the reporting person in this SC 13G/A filing?
The reporting person is TCG Crossover GP I, LLC, a Delaware-based entity, as stated in the filing.
What is the subject company of this filing?
The subject company is Taysha Gene Therapies, Inc., identified by the CIK 0001806310 and CUSIP 877619106.
How many shares with sole voting power does TCG Crossover GP I, LLC beneficially own in Taysha Gene Therapies, Inc. according to this filing?
TCG Crossover GP I, LLC beneficially owns 0 shares with sole voting power in Taysha Gene Therapies, Inc., as explicitly stated in item 5 of the filing.
What was the date of the event that triggered this filing?
The date of the event which requires the filing of this statement was December 31, 2023.
Which rule under the Securities Exchange Act of 1934 is this Schedule 13G filed under?
This Schedule 13G is filed under Rule 13d-1(c), as indicated by the checked box on the cover page.
Filing Stats: 1,370 words · 5 min read · ~5 pages · Grade level 8.8 · Accepted 2024-02-09 16:24:55
Key Financial Figures
- $0.00001 — Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class o
Filing Documents
- d860063dsc13ga.htm (SC 13G/A) — 55KB
- 0001193125-24-030082.txt ( ) — 56KB
From the Filing
SC 13G/A 1 d860063dsc13ga.htm SC 13G/A SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Taysha Gene Therapies, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 877619106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 877619106 13G 1. NAMES OF REPORTING PERSONS TCG Crossover GP I, LLC 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)(b) 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 2,912,861 (1) 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 2,912,861 (1) 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,912,861 (1) 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.6% (2) 12. TYPE OF REPORTING PERSON (see instructions) OO (1) Consists of 2,912,861 shares of Common Stock (as defined in the Original Schedule 13G as defined in the Explanatory Note below) of the Issuer (as defined in the Original Schedule 13G) held of record by TCG Crossover I (as defined in the Explanatory Note below). TCG Crossover GP I (as defined in the Explanatory Note below) is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities. (2) Based on 186,960,193 shares of Common Stock outstanding as of November 14, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, filed with the Securities and Exchange Commission (the Commission ) on November 14, 2023 (the Form 10-Q ). CUSIP No.877619106 13G 1. NAMES OF REPORTING PERSONS TCG Crossover Fund I, L.P. 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)(b) 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 2,912,861 (1) 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 2,912,861 (1) 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,912,861 (1) 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.6% (2) 12. TYPE OF REPORTING PERSON (see instructions) PN (1) Consists of 2,912,861 shares of Common Stock of the Issuer held of record by TCG Crossover I. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities. (2) Based on 186,960,193 shares of Common Stock outstanding as reported by the Issuer in its Form 10-Q. CUSIP No. 877619106 13G 1. NAMES OF REPORTING PERSONS Chen Yu 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)(b) 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION United States of America NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 2,912,861 (1) 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 2,912,861 (1) 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,912,861 (1) 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 1.6% (2) 12. TYPE OF REPORTING PERSON (see instructions) IN (1) Consists of 2,912,861 shares of Common Stock of the Issuer held of record by TC